Streetbeat News

AMWL

American Well Corporation

Industry

Medical - Healthcare Information Services

American Well Corporation operates as a telehealth software company that enables digital delivery of care for healthcare. The company products offer urgent care; scheduled visits; acute behavioral health; telestroke; pediatrics; retail health, school health, and home settings. Its application offers urgent care; pediatrics; therapy; menopause nutrition; end-stage renal disease and dialysis; dermatology care; behavioral health therapy; and musculoskeletal care. The company also provides telemedicine equipment, including telemedicine carts, peripherals, tyto care, TV kits, tablets, and kiosks. American Well Corporation was incorporated in 2006 and is headquartered in Boston, Massachusetts.

Open

10.85

Mkt cap

163M

Volume

27K

High

11.13

P/E Ratio

-0.74

52-wk high

29.00

Low

10.29

Div yield

N/A

52-wk low

5.00

Amwell has sold its virtual psychiatric care business, Amwell Psychiatric Care, to Avel eCare in an all-cash transaction. This divestment is part of Amwell's strategy to focus on key growth initiatives and improve efficiencies. The company has reiterated its guidance for 2024.

Portfolio Pulse from

January 09, 2025 | 1:15 pm

Amwell has announced that its CFO, Mark Hirschhorn, will expand his role to include Chief Operating Officer responsibilities, overseeing operational and growth strategies.

Portfolio Pulse from

December 18, 2024 | 9:45 pm

Needham analyst Ryan MacDonald has reiterated a Hold rating on American Well (NYSE:AMWL).

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 9:30 am

American Well (NYSE:AMWL) reported a Q3 2024 GAAP EPS of $(2.87), beating the estimate of $(3.50), but sales of $61.046M missed the $63.272M estimate. Sales decreased by 1.41% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 8:31 pm

Several healthcare stocks experienced significant price movements in Tuesday's pre-market session. Notable gainers include GlycoMimetics, Shuttle Pharmaceuticals, and Lixte Biotechnology, while TransMedics Group and Cardio Diagnostics Holdings were among the biggest losers.

Portfolio Pulse from Benzinga Insights

October 29, 2024 | 12:08 pm

In Tuesday's pre-market session, several healthcare stocks experienced significant price movements. GlycoMimetics, Shuttle Pharmaceuticals, Lixte Biotechnology, NovaBay Pharmaceuticals, Immuron, and Protagenic Therapeutics saw notable gains. Conversely, TransMedics Group, Cardio Diagnostics Holdings, Biora Therapeutics, Trinity Biotech, American Well, and Healthcare Triangle experienced declines.

Portfolio Pulse from Benzinga Insights

October 29, 2024 | 12:08 pm

Amwell has announced the appointment of Mark Hirschhorn as the new Chief Financial Officer, effective October 21, succeeding Robert Shepardson.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 8:32 pm

Amwell has partnered with Hello Heart to offer a cardiovascular solution as part of its clinical programs on the Amwell Converge platform. This allows Amwell's health plan clients to provide the Hello Heart solution to members with cardiovascular risk factors.

Portfolio Pulse from Benzinga Newsdesk

October 08, 2024 | 11:16 am

Needham analyst Ryan MacDonald has reiterated a Hold rating on American Well (NYSE:AMWL).

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 11:05 am

Wells Fargo analyst Stan Berenshteyn maintains an Equal-Weight rating on American Well (NYSE:AMWL) but lowers the price target from $40 to $15.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 3:19 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.